BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22882706)

  • 1. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Radke OC; Kuhlisch E; Hartmann A; Weiss N; Werth S
    J Thromb Haemost; 2012 Oct; 10(10):2045-52. PubMed ID: 22882706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
    Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
    Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
    Mismetti P; Samama CM; Rosencher N; Vielpeau C; Nguyen P; Deygas B; Presles E; Laporte S;
    Thromb Haemost; 2012 Jun; 107(6):1151-60. PubMed ID: 22476471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.
    Long A; Zhang L; Zhang Y; Jiang B; Mao Z; Li H; Zhang S; Xie Z; Tang P
    J Thromb Thrombolysis; 2014 Oct; 38(3):299-305. PubMed ID: 24402194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
    Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
    Yoshida Rde A; Yoshida WB; Maffei FH; El Dib R; Nunes R; Rollo HA
    Ann Vasc Surg; 2013 Apr; 27(3):355-69. PubMed ID: 23351997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
    Turpie AG; Haas S; Kreutz R; Mantovani LG; Pattanayak CW; Holberg G; Jamal W; Schmidt A; van Eickels M; Lassen MR
    Thromb Haemost; 2014 Jan; 111(1):94-102. PubMed ID: 24154549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos A; Tapson V
    J Thromb Thrombolysis; 2011 May; 31(4):407-16. PubMed ID: 21359646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
    Trkulja V; Kolundzic R
    Croat Med J; 2010 Apr; 51(2):113-23. PubMed ID: 20401953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
    Turpie AG; Schmidt AC; Kreutz R; Lassen MR; Jamal W; Mantovani L; Haas S
    Vasc Health Risk Manag; 2012; 8():363-70. PubMed ID: 22701330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
    Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
    Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery.
    Ohta H; Miyake T; Shimizu T; Sonoda H; Ueki T; Kaida S; Yamaguchi T; Iida H; Tani M
    World J Surg Oncol; 2019 Jun; 17(1):110. PubMed ID: 31248419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review.
    Hull RD; Liang J; Bergqvist D; Yusen RD
    Thromb Haemost; 2014 Feb; 111(2):199-212. PubMed ID: 24154501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of fondaparinux for the prophylaxis of venous thromboembolism after resection for colorectal cancer.
    Tsutsumi S; Yajima R; Tabe Y; Takaaki T; Fujii F; Morita H; Kigure W; Kato T; Yamauchi H; Suto T; Asao T; Kuwano H
    Hepatogastroenterology; 2012; 59(120):2477-9. PubMed ID: 23169180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.
    Farias-Eisner R; Horblyuk R; Franklin M; Lunacsek OE; Happe LE
    Curr Med Res Opin; 2009 May; 25(5):1081-7. PubMed ID: 19298219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.